Patent Law Weblog
recent posts
- Apple v. Squires: USPTO Director Has Unlimited Discretion on IPR Institution
- The Ghost in the Machine: Why GenAI Can Be Both a Brilliant Researcher and a Terrible Advocate
- Bayer Files Suit Against Trio of COVID-19 Vaccine Makers
- Allen v. Cooper (4th Cir. 2026)
- To Require an Inventor ID, or Not to Require an Inventor ID – That Is the Question
about
Month: September 2007
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma cases, and a few interesting cases will be selected for periodic monitoring. Adams Respiratory Therapeutics, Inc. et al v. Perrigo Company et al.2:07-cv-04619; filed September 27, 2007 in the District Court of New Jersey…
-
October 10-12, 2007 – Stem Cells European Business Summit – Edinburgh, Scotland October 12, 2007 – Intellectual Property Law Summit 2007 (West LEGALWorks and Intellectual Property Law Association of Chicago) – Chicago, IL October 16, 2007 – New Patent Rules Update: Implications of Compliance (World Research Group) October 25-26, 2007 – Biotech and Pharma Public-Private…
-
By Kevin E. Noonan — As Patent Docs reported on Wednesday, Patent Commissioner John Doll (at right) was the luncheon speaker at the American Conference Institute’s Biotech Patents conference in Boston. During the question-and-answer session, the Commissioner was asked about information one participant had received from a Patent Office official regarding divisional application…
-
Eli Lilly & Co. v. Emisphere Techs., Inc., No. 03-cv-1504-DFH (S.D. Ind.) By Robert Dailey — This week Eli Lilly agreed to pay $18 million to settle its contract and patent dispute with biotech start-up Emisphere. In the late 90s, the two companies had agreed to work together to develop an oral delivery…
-
By Donald Zuhn — Last Friday, the Federal Circuit reversed a District Court’s finding on summary judgment that eight generic drug manufacturers did not infringe U.S. Patent No. 6,054,482 (the ‘482 patent), and affirmed the District Court’s construction of two disputed claim limitations. Plaintiffs-Appellants Warner Lambert Co., Pfizer Inc., and Gödecke Aktiengesellschaft (Warner…
-
By Sherri Oslick — Late last week, Novartis and Ranbaxy filed a joint stipulation and dismissal in their pending lawsuit over generic valsartan, the active ingredient in Novartis’ Diovan®, used to treat hypertension. The suit, filed on August 9, 2007 in the District Court of New Jersey (see previous report), had been pending…
-
By Kevin E. Noonan — The American Conference Institute is holding its Biotech Patents conference this week in Boston, and the lunchtime speaker was John Doll, Commissioner for Patents. Commissioner Doll (at right) is the happy face of the U.S. Patent and Trademark Office: smiling, self-deprecating, and charming while he espouses the Patent…
-
By Christopher P. Singer — As previously reported on Patent Docs, the biotechnology and chemical pharmaceuticals technology groups at the U.S. Patent Office held their most recent quarterly customer partnership meeting on September 12, 2007. While we were unable to attend the webcast on the day of the meeting, we will summarize a…
-
By Jason Derry — Array BioPharma Inc. and Celgene Corp. have announced an agreement to collaborate in discovery, development, and commercialization of therapeutics for cancer and inflammation. Under the terms of the agreement, Celgene will pay Array BioPharma $40 million at the outset of the collaboration. Array and Celgene will mutually select four…
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma cases, and a few interesting cases will be selected for periodic monitoring. Elan Corporation PLC v. Teva Pharmaceuticals USA Inc.1:07-cv-00552; filed September 14, 2007 in the District Court of Delaware Infringement of U.S. Patent…
Patent Docs 